NEW YORK (360DX) – Biomarker-based diagnostics firm Kypha announced it has acquired diagnostics platform and contract development company Biosensia.
Biosensisa will operate as a wholly owned subsidiary of Kypha. Further financial and other terms of the deal were not disclosed.
Kypha, based in St. Louis, develops specialized biomarker tests for monitoring immune status and inflammation. Its platforms measure complement and other immune status biomarkers. Its Comp Act testing platform includes a portable instrument with multiple single-use assay cassettes to measure complement activation biomarkers from a small volume of blood.
Irish firm Biosensia has developed a point-of-care diagnostic system called RapiPlex, which it said can produce quantitative and qualitative laboratory-quality test results. According to the company's website, RapiPlex comprises a disposable assay cartridge and a small tabletop instrument. It can run simultaneous multiplex testing up to 24 analytes and is compatible with whole blood, plasma, serum, urine, saliva, and milk. Results can be achieved in five to 15 minutes.
Biosensia also offers contract assay development and manufacturing.
Combined, the two firms' platforms "promise to quickly and accurately detect meaningful changes in immune-mediated disease activity for more effective treatment decisions and patient care," Kyph said in a statement.
"With continued growth in biologic and cellular therapies targeting complement- and immune-mediated mechanisms, the need for these solutions is growing rapidly," Kypha CSO Martin Schmidt said in a statement. "This acquisition reinforces our position as the ideal diagnostic partner for stratifying patient populations and tailoring treatment for each patient suffering from immune-mediated conditions."